Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer

医学 药代动力学 肺癌 内科学 四分位间距 肿瘤科 免疫组织化学 癌症 队列
作者
Zhijie Wang,Jianming Ying,Jiachen Xu,Pei Yuan,Jianchun Duan,Hua Bai,Changyuan Guo,Lin Li,Zhenlin Yang,Rui Wan,Kailun Fei,Zhe Zhao,Xinyang Du,Junhui Zhao,Ning Lv,Jie Wang
出处
期刊:JAMA network open [American Medical Association]
卷期号:3 (10): e2013770-e2013770 被引量:49
标识
DOI:10.1001/jamanetworkopen.2020.13770
摘要

Importance: Programmed cell death 1 (PD-1) antibodies have shown substantial survival benefit in patients with advanced non-small cell lung cancer (NSCLC). Toripalimab is a promising and practicable PD-1 antibody; however, its performance in NSCLC has not been established. Objectives: To assess the safety, antitumor activity, and pharmacokinetics of toripalimab in patients with advanced NSCLC and to evaluate the utility of JS311, a novel PD ligand 1 (PD-L1) immunohistochemistry (IHC) assay. Design, Setting, and Participants: This single-arm open-label phase 1 trial enrolled 41 patients with advanced NSCLC that had progressed after at least 3 lines of therapy between September 21, 2017, and June 5, 2018, with a median (interquartile range) follow-up of 14.9 (3.2-22.5) months and included a cohort study comparing JS311 with other PD-L1 IHC assays that included 280 NSCLC specimens collected from January 1, 2016, to May 21, 2018. Data collection was conducted from September 21, 2017, to September 27, 2019, and analysis was conducted from September 27, 2019, to December 30, 2019. Exposure: Enrolled patients were administered a single dose of toripalimab, under 2 manufacturing processes and scales (200 L and 500 L), for safety and pharmacokinetic analysis within 28 days, followed by subsequent multidose infusions every 2 weeks. PD-L1 expression was determined by IHC with JS311, comparing its results with results from 22C3, 28-8, and SP263 simultaneously. Main Outcomes and Measures: Progression-free survival (PFS) and overall survival (OS), estimated by Kaplan-Meier curves, and continuous variables compared by t test or Mann-Whitney test. Correlations between PD-L1 IHC antibodies were evaluated by Spearman correlation test. Results: A total of 41 patients (29 [70.7%] men) with a median (interquartile range) age of 59 (53 to 63) years who experienced disease progression following chemotherapy were included. The most common treatment-related adverse events were rash (6 [14.6%]), increased amylase level (5 [12.2%]), and increased aspartate aminotransferase level (5 [12.2%]). In 35 patients included in the pharmacokinetic analysis, drug exposure and area under curve after 1 dose was similar under both manufacturing processes and scales (mean [SD] for 200-L group: 12 465.28 [4128.17] hour × μg/mL; for 500-L group: 12 331.42 [2472.58] hour × μg/ml). In 28 patients included in the response and survival analysis, the median PFS and OS were 2.8 (95% CI, 2.7 to 4.6) months and 13.8 months (95% CI, 10.0 months to not reached), respectively. Stratified by PD-L1 tumor proportion score of at least 50%, 1% to 49%, and less 1%, median PFS rates were 11.2 months (95% CI, 2.3 months to not evaluable), 2.3 (95% CI, 1.7 to 2.7) months, and 2.8 (95% CI, 2.7 to 4.6) months, respectively. A total of 4 anti-PD-L1 IHC antibodies were compared during PD-L1 staining, using 280 NSCLC specimens. The consistency rates between the 4 antibodies were 80.8% to 89.5% (ρ, 0.619 to 0.790) and 93.3% to 95.5% (ρ, 0.691 to 0.773), with PD-L1 tumor proportion scores of 1% and 50% as cut points, respectively. Conclusions and Relevance: In this study, toripalimab exhibited encouraging antitumor activity and manageable safety profiles among patients with heavily treated NSCLC. The novel PD-L1 IHC antibody JS311 was highly consistent with previously verified PD-L1 IHC assays.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丘比特的应助被cbw采纳,获得10
1秒前
bkagyin的应助被弗洛伊德的梦采纳,获得10
1秒前
共享精神的应助被KisaragiSabrina采纳,获得10
1秒前
朴实凌旋完成签到,获得积分20
3秒前
zyyy发布了新的文献求助30
3秒前
顺利的楷瑞完成签到 ,获得积分20
3秒前
AgJnpChen完成签到,获得积分10
3秒前
4秒前
一字勇完成签到,获得积分10
4秒前
和谐如风发布了新的文献求助10
5秒前
feifei发布了新的文献求助10
5秒前
无极微光的应助被jiexika采纳,获得20
5秒前
顾矜的应助被小羊采纳,获得10
6秒前
6秒前
朴实凌旋发布了新的文献求助10
6秒前
molihuakai的应助被闪电先生采纳,获得10
8秒前
田様的应助被bow采纳,获得10
8秒前
molihuakai的应助被海绵宝宝采纳,获得10
8秒前
情怀的应助被开朗紫采纳,获得10
9秒前
Lucas的应助被宋宋采纳,获得10
9秒前
9秒前
9秒前
Arty完成签到 ,获得积分10
10秒前
yosh完成签到 ,获得积分10
10秒前
1234567890完成签到 ,获得积分10
10秒前
11秒前
11秒前
Jing完成签到,获得积分20
12秒前
12秒前
past完成签到 ,获得积分10
13秒前
Essie完成签到,获得积分10
13秒前
14秒前
okk发布了新的文献求助10
14秒前
14秒前
15秒前
路口发布了新的文献求助10
16秒前
郭佳杰发布了新的文献求助10
16秒前
16秒前
syalonyui完成签到,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527